# Tumour-bed biopsy after neoadjuvant therapy

Source: https://onco.cc/terms/biopsy-after-neoadjuvant-therapy/  
OnCo record `biopsy-after-neoadjuvant-therapy` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sampling the former tumour site after treatment can miss scattered residual cancer, so a negative biopsy needs its study population and sampling method.

## Summary

Image-guided biopsy after preoperative systemic treatment tests selected parts of the former breast tumour bed. Diagnostic accuracy studies compare it with subsequent surgery; an omission study instead follows selected people without breast surgery. These designs answer different questions.

## Fields

- Kind: Term
- Last checked: 2026-11-10

## Notes

- In RESPONDER, 398 women with stage I to III breast cancer of all biological subtypes and an imaging response were analysed. Vacuum-assisted biopsy missed residual cancer in 37 of the 208 women whose surgery found it: a false-negative rate of 17.8% (95% confidence interval 12.8% to 23.7%). Of the 37 misses, 20 had minimal residual tumour smaller than 5 mm. Exploratory analyses reported no false negatives with the largest-volume 7-gauge needle and a 6.2% false-negative rate (95% confidence interval 3.4% to 10.5%) when imaging and biopsy were combined. These refinements do not establish general omission safety.
- The 2025 single-arm omission study enrolled 50 women aged at least 40 with HER2-positive or triple-negative cT1-2N0-1M0 disease and an imaging residual lesion smaller than 2 cm. After at least twelve 9-gauge vacuum cores, 31 had no residual breast cancer on biopsy and received radiotherapy without breast surgery. No ipsilateral breast recurrences occurred at median follow-up 55.4 months. Patients initially node-positive still underwent targeted axillary dissection. This small uncontrolled study calls for confirmation.
- Fictional accuracy exercise: surgery finds residual cancer in 40 of 100 people. Biopsy misses 8 of those 40, while all 60 without residual cancer test negative. False-negative rate is 8/40 = 20%; negative predictive value is 60/68, about 88%. The denominators differ. A breast sample does not establish axillary status or mapped surgical margins. False-negative rate uses all residual cancers as its denominator; negative predictive value uses negative biopsies and varies with prevalence and selection.
- A diagnostic clip and image guidance locate the former breast tumour bed, and cores sample selected positions. Pathology looks for residual invasive and in-situ disease; diagnostic accuracy studies then use surgery as the reference. Scattered residual cells can fall between samples. Imaging response alone does not prove pathological complete response.
- Tasoulis analysed 166 women from three centres using surgery as the reference; 143 underwent vacuum-assisted sampling and 23 core-cut biopsy. In 159 representative biopsies, false-negative rate was 18.7% (95% confidence interval 10.6% to 29.3%). Among 76 with complete or partial clinical response, imaging abnormality no larger than 2 cm and at least six vacuum samples, it was 3.2% (0.1% to 16.7%) and negative predictive value 97.4% (86.5% to 99.9%). The TNBC subgroup had pCR in 39 of 59. These selected estimates do not establish omission safety.
- NRG-BR005 was a prospective nonrandomised phase 2 study of marker-directed stereotactic multiple-core biopsy after chemotherapy. It included clinical complete responders with complete or near-complete trimodality imaging response. Of 101 evaluable patients, surgery found residual invasive or in-situ disease in 36. Sensitivity was 50% (95% confidence interval 32.9% to 67.1%) and negative predictive value 78.3% (67.9% to 86.6%). The authors did not support omitting surgery using these criteria. A retrospective central review found that only 62 of 101 met the imaging eligibility criteria; this exploratory post hoc analysis does not replace the main result.
- For these biopsy studies, breast pCR definitions can require no invasive or in-situ disease, while other breast pCR endpoints allow residual in-situ disease and include nodal status. Name the protocol definition. The 2022 omission report and its 2025 update follow the same selected cohort: no ipsilateral breast recurrences among 31 without breast surgery at median follow-up 26.4 and 55.4 months respectively. They are not independent replications.
- A small single-arm cohort with zero recurrences leaves uncertainty without a randomised comparison. Sampling does not provide the oriented margins or complete residual-burden assessment of resection, and breast biopsy does not assess every axillary node. Missing residual disease can also miss information used for further treatment decisions. These studies support continued investigation rather than a general rule to omit surgery.

## Sources

- Heil et al., RESPONDER, 2022: https://pubmed.ncbi.nlm.nih.gov/32657944/
- Kuerer et al., preplanned omission outcomes, 2025: https://pubmed.ncbi.nlm.nih.gov/40152443/
- Tasoulis et al., pooled diagnostic data, 2020: https://pubmed.ncbi.nlm.nih.gov/33026457/
- Basik et al., NRG-BR005, 2025: https://pubmed.ncbi.nlm.nih.gov/40332918/
- Kuerer et al., original omission outcomes, 2022: https://pubmed.ncbi.nlm.nih.gov/36306810/

## Connected records

- terms: [Core needle biopsy and fine-needle aspiration (FNA)](https://onco.cc/terms/core-needle-biopsy/), [Pathologic complete response (pCR)](https://onco.cc/terms/pcr/), [Surgical resection specimen](https://onco.cc/terms/surgical-resection-specimen/)
- technologies: [Vacuum-assisted breast biopsy systems (Mammotome, EnCor, Eviva, Brevera)](https://onco.cc/technologies/vacuum-assisted-breast-biopsy/)

---
JSON: https://onco.cc/api/v1/entities/biopsy-after-neoadjuvant-therapy.json